Understanding The True Value Of Your Biopharma Product With Earlier Intelligence

Yvonne Spark, Consultant, Covance Market Access Services

In the initial stages of drug development, it is natural to focus on a compound’s novel mechanism of action and potential implications in a therapeutic area. But with ever increasing complexities surrounding global reimbursement requirements and greater barriers to market acceptance, biopharmaceutical developers must gain a deeper understanding of the current landscape surrounding their therapy’s healthcare marketplace. Developers need market insight to avoid the risk of advancing a product that the market simply does not want, while simultaneously recognizing the full value of their asset to maximize markets uptake.

This is why best-in-class companies, both small and large, are increasingly turning to early stakeholder research to guide their development strategy, inform crucial decision points and increase their commercial potential.